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Backgroundandpurpose: It is knownthatdrug-eluting stents (DESs) areassociatedwith in-stent restenosis
(ISR).However, the characteristics of neointimal tissue components according to themechanismand time
course of DES ISR have not been fully examined. The aim of this study was to characterize the in-stent
neointimal tissue components according to the phase of restenosis using radiofrequency signals from
40-MHz intravascular ultrasound (IVUS), called iMAP-IVUS (Boston Scientiﬁc Corp., Fremont, CA, USA).
Methods: IVUS examinations were performed in 37 angina patients (37 lesions) who underwent repeated
percutaneous coronary intervention (PCI) for the treatment of DES ISR. The patients were divided into
two groups according to the phase of restenosis: the early ISR group (E-IRS; ≤1 year) and the late ISR
group (L-ISR; >1 year).
Results: There were 18 patients in the E-ISR group and 19 patients in the L-ISR group. The mean follow-
up period between stent implantation and repeated PCI was 8.0±2.2 months in the E-IRS group and
40.4±23.9 months in the L-ISR group. The percentage of lipid components and relative necrotic vol-
ume were greater in the L-ISR group than in the E-ISR group (5.77±1.81% vs. 4.51±1.71%, p<0.05
and 12.20±2.97% vs. 8.61±2.33%, p<0.001, respectively). Furthermore, there was a positive correla-
tion between the follow-up duration after DES implantation in the L-ISR group and the presence of a
necrotic plaque component (r=0.49, p<0.05).
Conclusions: There were differences in the neointimal plaque characteristics after DES implantation
according to the phase of restenosis. This information may lead to a better understanding of the mecha-
nisms of DES ISR.
© 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.ntroduction
The use of drug-eluting stents (DESs) has remarkably reduced
he rate of angiographic restenosis and target lesion revasculariza-
ion (TLR) compared with that of bare-metal stents (BMSs) [1,2].
owever, there continues to be a low rate of in-stent resteno-
is (ISR) after DES placement, and its prevalence is not negligible
ecause the population treated with DES is large. The mean
ime from the ﬁrst percutaneous coronary intervention (PCI) to the
etection of ISR related to DES is approximately 12 months, and
he duration of ISR after DES implantation is longer than that
DOI of commentary article: http://dx.doi.org/10.1016/j.jjcc.2014.05.002.
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ttp://dx.doi.org/10.1016/j.jjcc.2014.03.001
914-5087/© 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reobserved after BMS implantation [3]. The precise reasons why DES
restenosis occurs remain unknown; however, somemechanisms of
ISR after DES implantation have been proposed. Possible reasons,
such as biological factors, mechanical factors, and technical factors
can be used to predict DES ISR [4]. In addition, previous anecdotal
clinical experience has provided evidence of late ISR occurring over
1 year after DES implantation, the so-called “late catch-up phe-
nomenon” [5]. However, the characteristics of neointimal tissue
components according to the mechanism and time course of DES
ISR have not been fully examined.
iMAP-intravascular ultrasound (IVUS) (iMAP, Boston Scientiﬁc
Corp., Fremont, CA, USA) is an IVUS imaging system used for tis-
sue characterization with 40-MHz radiofrequency [6]. The iMAP
software program (QIvus 2.0, Medis Medical Imaging Systems bv,
Leiden, The Netherlands) converts the signal pattern into a fre-
quency spectrum and then compares it with the spectra obtained
from various tissues at autopsy (data library) to ﬁnd the closest
served.
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atch. Since the different tissue types (ﬁbrotic, lipidic, necrotic,
nd calciﬁed) have distinctive spectra, iMAP technology can iden-
ify tissues fromthe frequency spectrumthatmost closely resemble
he tissues obtained on examination [7]. The purpose of this study
as to assess the long-term neointimal tissue components after
ES implantation using iMAP-IVUS and discuss the mechanisms
nd time course of DES ISR from the view point of neointimal tissue
haracterization.
aterials and methods
tudy population
In this single-center study, a total of 37 patients were selected
rom among 53 consecutive patients who underwent elective PCI
or DES-ISR and iMAP-IVUS examinations between July 2009 and
eptember 2013. The subjects included patients with stable angina
ectoris (SAP) patients (class I or II angina unchanged for more
han 2 months) or a positive stress test. The target lesion was ISR
fter DES implantation (>75% angiographic stenosis based on visual
stimation). In total, 16 patients were excluded due to recurrent
SR (n=6), stent fracture (n=4), visible thrombi on angiography
n=2), the inability of the IVUS imaging catheter to cross the ISR
esion into the distal vessel even when pre-dilatation was per-
ormed with a small balloon (n=2), detection on routine follow-up
ngiography (n=1), and inadequate IVUS imaging quality (n=1).
o patients were excluded as a result of stent malapposition, ISR
ue to stent gap, and duration of 30 days or less after the ﬁrst stent
mplantation. As a result, 37 patients (37 vessels) were analyzed.
arly ISR (E-ISR) was deﬁned as the ﬁrst ISR observed within 1
ear after DES implantation, whereas late ISR (L-ISR) was deﬁned
s the ﬁrst ISR observed >1 year after DES implantation. Type 2
iabetes mellitus was deﬁned as the use of oral hypoglycemic
gents or insulin to lower the blood glucose level, a known fas-
ing blood glucose value of ≥126mg/dl and/or a postprandial 2-h
lood glucose value of ≥200mg/dl. Hyperlipidemia was deﬁned
s a total cholesterol level of ≥220mg/dl, low-density lipopro-
ein cholesterol level of ≥140mg/dl, fasting triglyceride level of
150mg/dl, or medication use. Hypertension was deﬁned as a
ystolic blood pressure of ≥140mmHg, a diastolic blood pres-
ure of ≥90mmHg, or the use of an antihypertensive drug. The
stimated glomerular ﬁltration rate (eGFR) was calculated accord-
ng to the modiﬁcation of diet in renal disease (MDRD) equation:
GFR (ml/min/1.73m2) =194×Cr−1.094 × age−0.287 (corrected for
emales by multiplying with a factor of 0.739) [8]. Approval to con-
uct this study was obtained from the ethics committee of our
nstitute.
CI procedure
The patientswere pre-medicatedwith aspirin (100mg/day) and
lopidogrel (75mg/day) for at least 1 week before the procedure.
hey received intravenous unfractionated heparin immediately
rior to PCI in order to achieve an activated partial thromboplas-
in time of >250 s. None of the patients were given glycoprotein
Ib/IIIa inhibitors because these drugs have not been approved
n Japan. First, PCI was performed using the technique of pre-
ilatation with shorter balloons, a stent long enough to cover the
ntire area of balloon injury and post-dilatation within the stented
esions employing short, high-pressure balloons. The implantation
f two stents was avoided in order to account for stent gaps, and
verwrapping stents were implanted in cases involving implanta-
ion of two or more DESs. If the IVUS catheter could not cross the
esiondue to severe stenosis or occlusion, dilatationwas performed
ith a small balloon prior to advancing the catheter. The coronarylogy 64 (2014) 423–429
ﬂow before the PCI procedure was evaluated based on the throm-
bolysis in myocardial infarction (TIMI) grade [9]. The pattern of ISR
was described using the Mehran classiﬁcation [10].
IVUS imaging and analysis
IVUS was performed before PCI and after the intracoronary
administration of 125–250g of nitroglycerin. The data were
acquired using a 40-MHz IVUS catheter (Atlantis SR Pro, Boston
Scientiﬁc). The catheter was advanced beyond the target lesion,
and imaging was performed during automatic pullback at a speed
of 0.5mm/s. The IVUS data were stored on a hard disk for an
off-line analysis,whichwasperformed independentlyby twoexpe-
rienced analysts who were unaware of the angiographic ﬁndings
or baseline clinical and lesion characteristics. The ﬁrst observer
repeated a blind analysis of all the data at two separate time
points (with an interval of at least 1 month between the two
analyses). A quantitative analysis of the gray-scale IVUS images
was performed according to the criteria of the American College
of Cardiology Clinical Expert Consensus Document on IVUS [11].
The lesions were qualitatively analyzed using the iMAP software
program. The external elastic membrane (EEM), stent and lumen
cross-sectional area (CSA) were measured. Using the iMAP soft-
ware program, the contours of the EEM, stent, and lumen interface
were detected semiautomatically. The neointimal plaque CSA was
calculated as the stent CSA minus the lumen CSA, and the neoin-
timal plaque burden was calculated as the neointimal plaque CSA
divided by the stent CSA. The region of interestwas placed between
the luminal border and the inner border of the struts to avoid stent
strut artifacts (Fig. 1A and B). The minimum lumen site of the cul-
prit lesion was identiﬁed based on axial and longitudinal plaques.
If there were several slices with equal lumen sizes, the one with
the largest EEM and plaque CSA was selected. The lesion length
was deﬁned as the segment between the distal to proximal refer-
ence sites that appeared normal within an area 5mm proximal and
distal to the lesion. The proximal and distal references were the
single slices with the largest lumen and the smallest plaque bur-
den within an area 5mm proximal and distal to the lesion, before
any large side branch. Once a complete set of CSA measurements
and the lesion length were obtained, the volumetric analysis was
performed automatically.
iMAP-IVUS tissue characterization
The iMAP-IVUS analysis classiﬁed the plaques into four tissue
components and produced color images (green for ﬁbrotic plaque,
yellow for lipidic plaque, red for necrotic plaque, and blue for calci-
ﬁedplaque) (Fig. 1A andB). The absolute plaque area (mm2), plaque
volume (mm3), and percentage of each tissue component were
determined. The percent plaque volume was deﬁned as the ratio
of each plaque volume to the neointimal plaque volume (%ﬁbrotic,
%lipidic, %necrotic, and %calciﬁed). Using the iMAP software pro-
gram, we traced the EEM, stent, and lumen CSA semiautomatically,
while also analyzing tissue characteristics and calculating the abso-
lute plaque area (mm2), plaque volume (mm3), and percentage of
each tissue component automatically. In addition, the plaque that
was unsuitable for the analysis due to acoustic shadowing behind
calciﬁcation or a wire artifact was removed automatically.
The application of iMAP-IVUS for tissue characterization has not
yet been validated for use with in-stent neointimal tissue. How-
ever, we substituted the above four tissue components for the
in-stent neointimal tissue. The intra-observer variability yielded
good concordance for the plaque volume and plaque components
on iMAP-IVUS: r=0.94 for plaque, r=0.93 for the necrotic compo-
nent. The inter-observer variability was acceptable: r=0.88 for the
lumen and r=0.82 for the necrotic component.
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Fig. 1. (A) Example of early in-stent restenosis plaque characterization using gray-scale intravascular ultrasound (IVUS) and iMAP-IVUS. (a) An 84-year-old male underwent
zotarolimus-eluting stent (ZES) implantation (white solid arrow) at the mid left anterior descending artery for stable angina. (b) After 8 months, he was suspected to have
stable angina, and coronary angiography was performed again, which revealed restenosis in the mid lesion at the ZES implantation site. (c)–(e) Cross-sectional gray-scale
IVUS image (upper) and iMAP-IVUS image (lower) of the proximal site (c), minimum lumen site (d) and distal site (e) before coronary intervention at the time of ZES
restenosis (b). The most external circle indicates the external elastic membrane, the middle circle indicates the stent and the most internal circle indicates the lumen area
(the most external circle on the iMAP-IVUS image was eliminated from the analysis). The region of interest was placed between the luminal border and the inner border of
the strut in order to avoid stent strut artifacts, and acoustic shadowing behind the wire artifact was removed automatically. The ﬁbrotic, lipidic, necrotic, and calciﬁed relative
volumes in the neointimal plaque were 81.3%, 1.6%, 3.5%, and 8.8%, respectively. Thick ﬁbrotic neointima and reduced lipidic and necrotic neointimal plaque volumes were
observed. Reduced lipidic and necrotic plaques were distributed around the stent after ZES implantation. (B) Example of late in-stent restenosis plaque characterization using
gray-scale IVUS and iMAP-IVUS. (a) A 69-year-old male underwent sirolimus-eluting stent (SES) implantation (white solid arrow) at the proximal left circumﬂex artery for
stable angina. (b) After 62 months, he was suspected to have stable angina, and coronary angiography was performed again, which revealed restenosis in the proximal lesion
at the SES implantation site. (c)–(e) Cross-sectional gray-scale IVUS image (upper) and iMAP-IVUS image (lower) of the proximal site (c), minimum lumen site (d) and distal
site (e) before coronary intervention at the time of SES restenosis (b). The ﬁbrotic, lipidic, necrotic, and calciﬁed relative volumes in the neointimal plaque were 73.5%, 7.3%,
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i3.0%, and 3.5%, respectively. Greater lipidic and necrotic neointimal plaque volum
hat neoatherosclerosis had occurred in the SES restenosis lesion.
tatistical analysis
Continuous variables are expressed as mean± standard devi-
tion, while discrete variables are presented as numbers and
ercentages. Differences in the mean values between the groups
ere assessed using the unpaired Student’s t-test. Categorical data
ere compared using chi-square statistics or Fisher’s exact test.
linear regression analysis was used to evaluate the correlations
etween the follow-up duration after DES implantation according
o the phase of restenosis and the plaque component using Pearson
orrelation coefﬁcients. A two-sided p-value of <0.05 was required
or statistical signiﬁcance. The data were analyzed using the SPSS
9.0 software package (SPSS, Inc., Chicago, IL, USA).
esults
atient characteristicsThe baseline patient characteristics are shown in Table 1. There
ere 18 patients (18 vessels) in the E-ISR group and 19 patients
19vessels) in theL-ISRgroup. Therewerenosigniﬁcantdifferences
n age, gender, or traditional coronary risk factors between the twore observed following a long follow-up period after SES implantation, suggesting
groups. Only the eGFR values were higher in the E-ISR group than
in the L-ISR group (p<0.05).
Coronary angiography and procedure ﬁndings
The coronary angiography and procedure ﬁndings are summa-
rized in Table 2. The follow-up duration after DES implantation
was 8.0±2.2 months in the E-ISR group and 40.4±23.9 months
in the L-ISR group (p<0.0001). There were no signiﬁcant differ-
ences in diseased vessels or lesion sites. However, the number of
sirolimus-eluting stents (SESs) was higher in the L-ISR group than
in the E-ISR group (p<0.05). In addition, the L-ISR group tended
to more frequently exhibit TIMI grade 0 and total occlusion based
on the Mehran classiﬁcation in the angiographic ﬁndings than the
E-ISR group (p=0.05).
Gray-scale IVUS ﬁndingsThe gray-scale IVUS data are presented in Table 3. Pre-dilatation
was performedwith a small balloon prior to advancing the catheter
due to either severe stenosis or occlusion in four vessels (22.2%) in
the E-ISR group and ten vessels (52.6%) in the L-ISR group (p=0.11).
426 T. Araki et al. / Journal of Cardiology 64 (2014) 423–429
Table 1
Baseline characteristics.
E-ISR group
≤1 year (n=18)
L-ISR group
>1 year (n=19)
p-Value
Age 72.39±10.39 70.11±10.50 0.51
Male gender (%) 15 (83.3) 16 (84.2) 0.99
BMI 22.58±2.19 23.99±2.33 0.10
Smoking (%) 8 (44.4) 8 (42.1) 0.99
Prior MI (%) 3 (16.7) 5 (26.3) 0.75
Prior CABG (%) 1 (5.6) 1 (5.3) 0.99
Hypertension (%) 15 (83.3) 18 (94.7) 0.55
Hyperlipidemia (%) 16 (88.9) 13 (68.4) 0.26
Diabetes mellitus (%) 6 (33.3) 11 (57.9) 0.24
Insulin user (%) 0 (0) 3 (15.8) 0.24
Total cholesterol (mg/dl) 159.5±29.69 176.71±40.39 0.18
LDL-cholesterol (mg/dl) 86.94±28.95 105.61±35.86 0.09
HDL-cholesterol (mg/dl) 49.89±8.86 49.28±12.92 0.87
Fasting blood glucose (mg/dl) 122.06±28.14 136.69±40.47 0.21
Hemoglobin A1C (%) 6.22±0.76 6.38±0.86 0.55
eGFR (ml/min/1.73m2) 45.50±16.78 31.98±20.78 <0.05
Hemodialysis (%) 2 (11.1) 4 (21.1) 0.70
Ejection fraction (%) 60.83±8.62 54.47±10.92 0.06
Continue DAPT (%) 17 (94.4) 12 (63.2) 0.05
Statin use (%) 15 (83.3) 13 (68.4) 0.49
RAS inhibiter use (%) 13 (72.2) 12 (63.2) 0.81
The data are presented as n (%) of patients or mean± SD.
E-ISR, early in-stent restenosis; L-ISR, late in-stent restenosis; BMI, body mass index; MI, myocardial infarction; CABG, coronary artery bypass grafting; LDL, low-density
lipoprotein; HDL, high-density lipoprotein; eGFR, estimated glomerular ﬁltration rate; DAPT, dual anti-platelet therapy; RAS, renin–angiotensin system.
Table 2
Procedure and coronary angiography ﬁndings.
E-ISR group
≤1 year (n=18)
L-ISR group
>1 year (n=19)
p-Value
Follow-up duration (months) 8.02±2.20 40.37±23.88 <0.0001
Stent types
Sirolimus-eluting stent 0 (0) 7 (36.8) <0.05
Paclitaxel-eluting stent 9 (50.0) 7 (36.8) 0.63
Zotarolimus-eluting stent 6 (33.3) 3 (15.8) 0.38
Everolimus-eluting stent 3 (16.7) 1 (5.3) 0.55
Biolimus-eluting stent 0 (0) 1 (5.3) 0.99
Stent diameter (mm) 2.99±0.40 3.07±0.33 0.49
Total stent length (mm) 28.00±15.88 29.31±10.74 0.78
Number of stent 1.44±0.62 1.53±0.61 0.69
Diseased vessel (%)
Left main 1 (5.6) 0 (0) 0.96
Left anterior descending 12 (66.7) 9 (47.4) 0.39
Left circumﬂex 1 (5.6) 3 (15.8) 0.63
Right 4 (22.2) 7 (36.8) 0.53
Lesion site (%)
Proximal 12 (66.7) 15 (78.9) 0.63
Middle 5 (27.8) 3 (15.8) 0.62
Distal 1 (5.6) 1 (5.3) 0.99
TIMI ﬂow (%)
TIMI 0 1(5.6) 7 (36.8) 0.05
TIMI 1 0 (0) 1 (5.3) 0.99
TIMI 2 4 (22.2) 2 (10.5) 0.60
TIMI 3 13 (72.2) 9 (47.4) 0.23
Angiographic pattern of ISR (Mehran classiﬁcation) (%)
Focal
1A: articulation or gap 0 (0) 0 (0) –
1B: margin 6 (33.3) 4 (21.1) 0.63
1C: focal body 6 (33.3) 3 (15.8) 0.38
1D: multifocal 2 (11.1) 4 (21.1) 0.70
Diffuse
2: intra-stent 1 (5.6) 0 (0) 0.96
3: proliferative 2 (11.1) 1 (5.3) 0.95
4: total occlusion 1 (5.6) 7 (36.8) 0.05
Pre-dilatation using small balloon before IVUS catheter insertion 4 (22.2) 10 (52.6) 0.11
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ghe data are presented as n (%) of patients or mean± SD.
-ISR, early in-stent restenosis; L-ISR, late in-stent restenosis; TIMI, thrombolysis inith respect to the two-dimensional area of the minimum lumen
ite and the three-dimensional volumetric analysis, there were
o signiﬁcant differences in IVUS parameters between the two
roups.cardial infarction; ISR, in-stent restenosis; IVUS, intravascular ultrasound.iMAP-IVUS ﬁndings
Regarding the volumetric parameters of the plaque compo-
nents in the neointimal plaque, the lipidic and necrotic volumes
T. Araki et al. / Journal of Cardiology 64 (2014) 423–429 427
Table 3
Gray-scale intravascular ultrasound ﬁndings.
E-ISR group
≤1 year (n=18)
L-ISR group
>1 year (n=19)
p-Value
Gray-scale IVUS analysis (two dimensions) – minimum lumen site
EEM area (mm2) 16.04 ± 4.00 18.04 ± 5.39 0.21
Stent area (mm2) 7.55 ± 2.68 7.72 ± 2.40 0.84
Lumen area (mm2) 2.39 ± 0.94 2.35 ± 0.43 0.89
Neointimal plaque area (mm2) 5.16 ± 2.12 5.12 ± 2.30 0.96
EEM− lumen area (mm2) 13.65 ± 3.40 15.69 ± 5.30 0.18
%Neointimal plaque area burden (%) 66.81 ± 9.32 68.20 ± 9.63 0.66
%EEM− lumen plaque area burden (%) 84.99 ± 3.44 86.06 ± 4.13 0.40
Gray-scale IVUS analysis (three dimensions)
EEM volume (mm3) 303.05 ± 234.57 440.43 ± 286.91 0.12
Stent volume (mm3) 145.65 ± 113.74 207.60 ± 142.55 0.15
Lumen volume (mm3) 69.46 ± 43.21 96.41 ± 53.10 0.10
Neointimal plaque volume (mm3) 84.91 ± 18.33 111.19 ± 107.84 0.40
EEM− lumen volume (mm3) 233.59 ± 200.04 344.02 ± 246.42 0.14
%Neointimal plaque volume burden (%) 55.78 ± 15.06 48.80 ± 15.69 0.18
%EEM− lumen plaque volume burden (%) 75.32 ± 9.76 76.33 ± 7.73 0.73
Lesion length (mm) 19.31 ± 13.44 25.77 ± 15.27 0.18
The data are presented as mean± SD.
E-ISR, early in-stent restenosis; L-ISR, late in-stent restenosis; EEM, external elastic membrane; IVUS, intravascular ultrasound.
Table 4
Relative volumetric parameters of the plaque components of the neointimal tissue.
E-ISR group
≤1 year (n=18)
L-ISR group
>1 year (n=19)
p-Value
Fibrotic volume (%) 73.11 ± 6.31 73.05 ± 6.25 0.98
Lipidic volume (%) 4.51 ± 1.71 5.77 ± 1.81 <0.05
Necrotic volume (%) 8.61 ± 2.33 12.20 ± 2.97 <0.001
Calciﬁed volume (%) 7.06 ± 4.32 5.00 ± 3.40 0.12
The relative volumes of the neointimal plaque tissue in the 37 iMAP-intravascular
ultrasound (IVUS) subset. The lipidic andnecrotic volumeswere signiﬁcantly greater
in the L-ISR group than in the E-ISR group.
T
E
w
g
8
v
E
F
n
g
m
Fig. 3. Correlations between the duration after DES implantation and the necrotiche data are presented as mean± SD.
-ISR, early in-stent restenosis; L-ISR, late in-stent restenosis.
ere signiﬁcantly greater in the L-ISR group than in the E-ISR
roup (5.77±1.81% vs. 4.51±1.71%, p<0.05 and 12.20±2.97% vs.
.61±2.33%, p<0.001, respectively) (Table 4 and Fig. 2). The plaque
olume found to be unsuitable for the analysiswas 4.6±2.5% in the
-ISR group and 2.8±2.0% in the L-ISR group.
ig. 2. Relative volumetric parameters of the lipidic and necrotic plaque compo-
ents of the neointimal tissue. The lipidic and necrotic volumes were signiﬁcantly
reater in the L-ISR group than in the E-ISR group. The data are presented as
ean± SD. E-ISR, early in-stent restenosis; L-ISR, late in-stent restenosis
plaque components. The correlations between the follow-up duration after DES
implantation and the necrotic plaque volumes according to the phase of resteno-
sis (early in-stent restenosis: E-ISR; ≤1 year and late in-stent restenosis: L-ISR;
>1 year). A linear regression plot showing a positive correlation between the follow-
up duration in the L-ISR group and the necrotic volume (Y=0.06X+9.30, r=0.49,
p<0.05). On the other hand, no signiﬁcant correlations were observed between the
follow-up duration in the E-ISR group and the necrotic volume (Y=−0.032X+8.87,
r=0.03, p=0.90). DES, drug-eluting stent.
Correlation between the follow-up duration after DES
implantation according to the phase of restenosis and the plaque
component
Therewasapositive correlationbetween the follow-upduration
after DES implantation in the L-ISR group and the necrotic volume
(Y=0.06X+9.30, r=0.49, p<0.05). On the other hand, no signiﬁcant
correlations were observed between the follow-up duration in the
E-ISR group and the necrotic volume (Y=−0.032X+8.87, r=0.03,
p=0.90) (Fig. 3) or between the follow-up duration and the lipidic
volume.
DiscussionUsing iMAP-IVUS, we demonstrated that the L-ISR group had
larger lipidic and necrotic plaque volumes after DES implantation
than the E-ISR group. Furthermore, a correlation between the long
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ollow-up duration after DES implantation and the necrotic plaque
olume was observed.
It is known that the mechanism underlying the development
f DES ISR involves biological factors, such as drug resistance or
ypersensitivity, mechanical factors, such as stent fracture, and
echnical factors, such as barotrauma outside of the stented seg-
ent, stent malapposition, and geographic misplacement (stent
ap) [3]. The aim of the present study was to assess the biologi-
al factors associated with DES ISR; therefore, mechanical factors
an be excluded as possible causative factors, including stent frac-
ure and technical factors, such as stent malapposition, stent gap,
nd restenosis within 30 days after the ﬁrst stent implantation.
n the present study, the lipidic and necrotic neointimal volumes
fterDES implantationwere signiﬁcantly smaller in theE-ISRgroup
han in the L-ISR group. A previous pathological study revealed that
hronic inﬂammation remainsandﬁbrindeposition frequentlyper-
ists around the implanted DES 3 months after stent implantation,
ndendothelialization is generally completedandneointima rich in
mooth muscle cells develops until 6–12 months after DES implan-
ation [12]. In addition, it has been reported that an overlying thick
eointimal layerwith concentric orientationof smoothmuscle cells
nd a peri-strut low-intensity area (PLIA), which is often detected
n low-intensity areas on pathology and optical coherence tomo-
raphy (OCT), are more frequently observed after DES than BMS. It
s considered that the PLIA may be an inﬂammatory cell inﬁltrate
round the stent strut associated with arterial healing [13]. These
athological ﬁndings are in agreement with the results that the
eointimal plaque associated with early-ISR DES consists of thick
eointimal ﬁbrotic tissue with reduced lipidic and necrotic plaque,
hich primarily exists around the stent strut, as shown in Fig. 1A.
On the other hand, the lipidic and necrotic neointimal vol-
mes after DES implantation were signiﬁcantly greater in the L-ISR
roup than in the E-ISR group. Postmortem pathological studies
ave revealed that the incidence of newly formed atherosclerotic
hanges within the neointimal tissue of the stented segment, so-
alled “neoatherosclerosis,” is one of the main causes of DES failure
nd a frequent ﬁnding in patients with DES that occurs earlier
han that observed in patients with BMS. The earliest implant
uration for lesions with a necrotic core is relatively short at
ES: 270 days and 360 days for SES and paclitaxel-eluting stent
PES) placement, respectively, whereas the earliest duration for
ecrotic core formation in BMS patients is longer at 900 days
14]. A recent OCT study demonstrated that, compared with DES
t <20 months post-implantation [the best cut-off for predict-
ng thin-cap ﬁbroatheromas (TCFA)-containing neointima], DES at
20 months post-implantation is associated with a higher inci-
ence of TCFA-containing neointima [15]. On virtual histology
VH)-IVUS, stents that have been implanted for a long period and
evelop late ISRexhibit an in-stent tissue composition that includes
necrotic core [16]. These pathological, OCT, and VH-IVUS ﬁnd-
ngs appear to be consistent with our data showing an association
etweena long follow-updurationafterDES implantationand large
ecrotic plaque volumes.
In this study, more patients were treated with SES implantation
n the L-ISRgroup than in theE-ISRgroup.Angioscopicdata indicate
hat the SES promotes the formation of lipid-rich, atherosclerotic
ellow neointima at 10 months and that intramural thrombi are
ore prevalent in newly formed yellow neointima [17]. As pre-
iously reported both at autopsy and in animal models, sirolimus
uppresses both smooth muscle cell and endothelial cell regrowth,
nd therefore may further enhance the occurrence of atheroscle-
otic changes [18]. Currently, data are mostly available for only
ES and PES, in which a trend toward more rapid neoatheroscle-
osis changes is more frequently observed in patients treated with
ES than in those treated with PES, indicating that differences in
rugs or polymers may inﬂuence neointimal tissues [19].logy 64 (2014) 423–429
Although IVUS has a lower resolution than OCT, IVUS-based
tissue characterization modalities contain more quantitative
parameters than qualitative neointimal assessments using OCT.
Furthermore, the possibility of performing qualitative assessments
of neointima tissue components has not been sufﬁciently recog-
nized because most neointima detected on gray-scale IVUS appear
to be homogenous [20]. iMAP-IVUS makes it possible to determine
not only tissue characterization, but also the absolute plaque vol-
ume and the ratio as well as the plaque area in lesions of interest
[21,22]. Therefore, we evaluated the neointimal tissue compo-
nents after DES implantation using iMAP-IVUS. Further studies
are required to validate our ﬁndings and conﬁrm the usefulness
of iMAP-IVUS, which may provide more in-depth information
regarding neointimal tissues after DES implantation.
This study has several limitations. First, this was a single-center,
retrospective study based on a relatively limited and small sample
size. Second, some areas of plaque were unsuitable for the anal-
ysis due to the presence of calciﬁcation and guidewire artifacts.
In addition, tissue compression during balloon angioplasty may
affect the characteristics of the tissue. Third, the present iMAP-
IVUS modality is unable to differentiate thrombi from other plaque
components. Although we excluded all cases of angiographically
detected thrombi and enrolled only SAP patients, nonacute coro-
nary syndrome patients, the presence of small thrombi within
in-stent neointimal tissue components may have resulted in incor-
rect tissue characterization [23]. Fourth, there are differences in
drugs, release kinetics, polymers, and stent platforms between
the different types of DES [24]. Currently, second-generation DES
devices are commonly used; however, the proportion of cases
involving second-generation DES was low in this study. Therefore,
it is difﬁcult to generalize the ﬁndings of this study to all cur-
rently used DES devices. Fifth, this study is not a true study of the
natural history of in-stent lesions, in which the same stents were
serially studied at different time periods after implantation. Sixth,
the present study analyzed only the minimum lumen site of the
ISR lesion and excluded other intermediate stented lesions that did
not require PCI. Finally, iMAP-IVUS has not been validated for use
in patients with in-stent neointimal tissue. Therefore, the charac-
teristics of in-stent neointimal tissue evaluated using iMAP-IVUS
may not reﬂect the precise features of in-stent neointimal tissue.
Conclusions
The present ﬁndings revealed that DES implantation for late ISR
is associated with increased amounts of lipidic and necrotic plaque
components. Our results suggest that the mechanisms of ISR after
DES implantation are different in the early and late phases after
DES implantation.
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